Vectorite Biomedical, Inc. engages in the provision of immune cell storage, biotechnology service, and test service. Its business includes preparation sales, immune cell collection and storage, and medical intermediary. Its products and services include dendritic cell vaccine (DC vaccine), anti-malignant natural killer cell (NK cell) preparation, immune cell storage service, and cell preparation safety testing service. The company was founded on December 23, 2004 and is headquartered in New Taipei, Taiwan.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company